- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01124786
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Pancreatic cancer is a very serious form of cancer. The majority of patients present with unresectable disease, and the condition is often not diagnosed until the cancer is relatively advanced. The standard first-line treatment for patients with unresectable pancreatic cancer is gemcitabine monotherapy. Unfortunately many of these patients fail to derive benefit from this treatment. No clinical or molecular marker has been established to predict benefit from gemcitabine therapy, so patients are treated empirically until evidence of disease progression or worsening performance status.
The potential for human equilibrative nucleoside transporter-1 (hENT1) expression to predict survival in gemcitabine-treated patients has been studied, and data suggest that patients with low levels of tumor cell hENT1 expression derive less benefit from gemcitabine treatment than patients with high levels of tumor cell hENT1 expression. These data support the hypothesis to be tested in this study that patients with pancreatic tumors expressing low levels of hENT1 will derive minimal benefit from gemcitabine, but will receive benefit from CO-1.01 (gemcitabine elaidate) which enters tumor cells in a hENT1-independent fashion.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 13353
- Charite Universitatsmedizin Berlin
-
Dresden, Alemanha, 01307
- Universitätsklinikum Carl Gustav Carus
-
Magdeburg, Alemanha, 39120
- Klinik der Otto-Von-Guericke-Universität Magdeburg
-
Ulm, Alemanha, 89081
- Medizinische Universitätsklinik Ulm, Abt. Innere Medizin I
-
-
Bayern
-
München, Bayern, Alemanha, 81377
- Ludwig-Maximilians-Universität, Medizinische Klinik und Poliklinikversität München
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Alemanha, 17475
- Klinikum der Ernst-Moritz-Arndt-Universität
-
-
Nordrhein-Westfalen
-
Bochum, Nordrhein-Westfalen, Alemanha, 44892
- Knappschaftskrankenhaus Bochum-Langendreer
-
-
Thueringen
-
Jena, Thueringen, Alemanha, 07740
- Universitätsklinikum Jena
-
-
-
-
-
Córdoba, Argentina, X5004FHP
- Clinica Universitaria Reina Fabiola
-
Santa Fe, Argentina, S3000FFU
- ISIS Centro especializado
-
-
Bahia Blanca
-
Buenos Aires, Bahia Blanca, Argentina, B8000FJI
- Policlínica Privada Instituto de Medicina Nuclear
-
-
Buenos Aires
-
Cuidad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Instituto Especializado Alexander Fleming
-
Loma Hermosa, Buenos Aires, Argentina, B1657BHD
- Hospital de Gastroenterología
-
-
-
-
New South Wales
-
New Lambton Heights, New South Wales, Austrália, 2305
- Newcastle Private Hospital
-
Port Macquarie, New South Wales, Austrália, 2444
- Port Macquarie Base Hospital
-
Wollongong, New South Wales, Austrália, 2500
- Southern Medical Day Oncology Care Centre
-
-
South Australia
-
Bedford Park, South Australia, Austrália, 5042
- Flinders Medical Centre
-
-
Victoria
-
Fitzroy, Victoria, Austrália, 3065
- Saint Vincent's Hospital
-
Wodonga, Victoria, Austrália, 3690
- Border Medical Oncology, Murray Valley Private Hospital
-
-
-
-
-
Rio de Janeiro, Brasil, 20231
- Instituto Nacional do Cancer
-
-
Distrito Federal
-
Brasilia, Distrito Federal, Brasil, 70840
- Hospital Universitario
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 60430-230
- Santa Casa de Misericordia de Belo Horizonte
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90610-000
- Hospital Sao Lucas - PUCRS
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90020
- Irmandade da Santa
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasil, 88034-000
- CEPON-Centro de Pesquisas Oncológicas
-
-
Sao Paulo
-
Barretos, Sao Paulo, Brasil, 14784-400
- Hospital do Cancer de Barretos
-
Jau, Sao Paulo, Brasil, 17210
- Fundacao Hospital
-
Santo Andre, Sao Paulo, Brasil, 09060-650
- Faculdade de Medicina do ABC
-
-
-
-
-
Brussels, Bélgica, 1200
- Cliniques Universitaires Saint Luc
-
Haine-Saint-Paul, Bélgica, 7100
- Centre Hospitalier de Jolimont-Lobbes
-
-
Antwerpen
-
Edegem, Antwerpen, Bélgica, 2650
- Universitair Ziekenhuis Antwerpen
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Cross Cancer Institute
-
-
-
-
Arizona
-
Glendale, Arizona, Estados Unidos, 85306
- Arizona Center for Hematology Oncology
-
-
California
-
Corona, California, Estados Unidos, 92879
- Wilshire Oncology Medical Group, Inc.
-
Los Angeles, California, Estados Unidos, 90033
- White Memorial Medical Center
-
Los Angeles, California, Estados Unidos, 90036
- Cancer Care Institute
-
Newport Beach, California, Estados Unidos, 92660
- Newport Cancer Care Medical
-
Oakland, California, Estados Unidos, 94609
- Hematology Oncology Associates
-
San Diego, California, Estados Unidos, 92123
- Sharp Clinical Oncology Research
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06102
- Hartford Hospital Clinical Research
-
Trumbull, Connecticut, Estados Unidos, 06611
- Oncology Associates of Bridgeport
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 21401
- Annapolis Oncology Center
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Virginia Piper Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- The Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- New Mexico Cancer Care Alliance
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Arena Oncology Associates, PC
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Bend Memorial Clinic
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Cancer Center Of The Carolinas
-
-
Texas
-
Corpus Christi, Texas, Estados Unidos, 78412
- Cancer Specialists of South Texas, P.A.
-
Harlingen, Texas, Estados Unidos, 78550
- Valley Cancer Associates
-
San Antonio, Texas, Estados Unidos, 78229
- South Texas Oncology and Hematology, PA
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
-
-
-
Ekaterinburg, Federação Russa, 620036
- Sverdlovsk Regional Oncology Center
-
Irkutsk, Federação Russa, 664035
- Regional Oncology Center
-
Krasnodar, Federação Russa, 350040
- Clinical Oncology Center #1
-
Kursk, Federação Russa, 305035
- Kursk Regional Oncology Center
-
Moscow, Federação Russa, 115478
- Blokhin Cancer Research Center
-
Novosibirsk, Federação Russa, 630047
- Novosibirsk, City Clinical Hospital #1
-
St. Petersburg, Federação Russa, 194291
- Leningrad Regional Clinical Hospital
-
St. Petersburg, Federação Russa, 195067
- Mechnikov St. Petersburg State Medical Academy
-
St. Petersburg, Federação Russa, 197785
- St. Petersburg City Oncology Center
-
Tambov, Federação Russa, 392013
- Tambov Regional Oncology Center
-
Tula, Federação Russa, 300053
- Tula Regional Oncology Center
-
Yaroslavl, Federação Russa, 150040
- Regional Clinical Oncology Hospital
-
-
Republic of Udmurtia
-
Izhevsk, Republic of Udmurtia, Federação Russa, 426067
- Republic Clinical Oncology Center
-
-
-
-
-
Bayonne Cedex, França, 64109
- Centre Hospitalier de la Côte Basque
-
Bordeaux, França, 33000
- Hôpital Saint André, Service d'Oncologie Médicale
-
Limoges Cedex, França, 87039
- Clinique Francois Chenieux
-
Montpellier, França, 34298
- Centre Regional de Lutte contre le Cancer Val d'Aurelle
-
Montpellier Cedex 5, França, 34295
- Centre Hospitalier Régional Universitaire Hôpital Saint Eloi
-
Saint Herblain cedex, França, 44805
- Centre Rene Gauducheau
-
Villejuif Cedex, França, 94805
- Institut Gustave-Roussy - Centre de Lutte Contre le Cancer
-
-
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Holanda, 1081 HV
- Vrije Universiteit Medisch Centrum
-
-
-
-
-
Milano, Itália, 20132
- Fondazione San Raffaele del Monte Tabor
-
Padova, Itália, 35128
- Instituto Oncologico Veneto, Oncologia Medica 1
-
Torrette di Ancona, Itália, 60020
- Ospedali Riuniti Di Ancona
-
Verona, Itália, 37134
- Centro Ricerche Cliniche Di Verona
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Itália, 40138
- Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
-
-
-
-
-
Kristiansand, Noruega, 4604
- Sørlandet Sykehus HF
-
Oslo, Noruega, 0407
- Oslo universitetssykehus, Ullevål
-
-
-
-
England
-
London, England, Reino Unido, W12 0HS
- Hammersmith Hospital
-
Manchester, England, Reino Unido, M20 4BX
- Christie Hospital
-
-
Scotland
-
Glasgow, Scotland, Reino Unido, G12 0YN
- Beatson West of Scotland Cancer Centre, Cancer Research UK Clinical Trials Unit (CTU)
-
-
-
-
-
Jonkoping, Suécia, 551 85
- Lanssjukhuset Ryhov
-
Linköping, Suécia, 581 85
- Linköping University Hospital
-
Växjö, Suécia, 351 85
- Växjö Centrallasarettet
-
-
-
-
-
Dnipropetrovsk, Ucrânia, 49102
- Dnipropetrovsk City Multispecialty Clinical Hospital #4, Department of Chemotherapy, Dnipropetrovsk State Medical Academy, Department of Oncology and Medical Radiology
-
Donetsk, Ucrânia, 83092
- Public Clinical Treatment and Prophylaxis Institution "Donetsk Regional Antitumor Center", Oncosurgery Department #6
-
Kharkiv, Ucrânia, 61070
- "Public Healthcare Institution ""Kharkiv Regional Clinical Oncology Center"", Abdominal Department
-
Kiev, Ucrânia, 03022
- National Cancer Institute, Department of Tumors of Abdominal Cavity and Retroperitoneum
-
Lviv, Ucrânia, 79031
- State Regional Diagnostics and Treatment Oncology Center, Chemotherapy Department
-
Mykolayiv, Ucrânia, 54044
- Mykolayiv Regional Oncology Center, Surgery Department #1
-
Uzhorod, Ucrânia, 88014
- Zakarpatya Regional Clinical Oncology Center, Chemotherapy Department
-
Zaporizhya, Ucrânia, 69032
- Clinical Facility: Public Institution "Zaporizhya City Clinical Hospital #3", Regional Center of Hepatic, Biliary Tract and Pancreatic Surgery, Surgery Department #1
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Metastatic pancreatic ductal adenocarcinoma (i.e., Stage 4).
- Histological/cytological confirmation of metastatic tissue (not primary tumor) by a central pathology laboratory (H&E stain) to ensure sufficient material is available for later hENT1 analysis.
- Adjuvant chemotherapy/radiotherapy ≥ 6 months prior to randomization.
- Palliative radiotherapy (if administered) ≥ 1 month prior to randomization.
- CT scan ≤30 days prior to randomization
- Performance Status (ECOG) 0 or 1.
- Estimated life expectancy ≥ 12 weeks.
- Age ≥ 18 years.
- Adequate hematological and biological function.
- Written consent on an Institutional Review Board/Institutional Ethics Committee-approved Informed Consent Form prior to any study-specific evaluation.
Exclusion Criteria:
- Prior palliative chemotherapy for pancreatic cancer.
- Radical pancreatic resections (e.g., Whipple procedure) are not allowed < 6 months prior to randomization. Exploratory laparotomy, palliative (e.g., bypass) surgery, or other procedures (e.g., stents) are not allowed < 14 days prior to randomization. In both cases the patient must be sufficiently recovered and stable.
- Symptomatic brain metastases.
- Participation in other investigational drug clinical studies ≤ 30 days prior to randomization.
- Concomitant treatment with prohibited medications.
- History of allergy to gemcitabine or eggs.
- Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled intercurrent illness including active infection, arterial thrombosis, symptomatic pulmonary embolism).
- Any disorder that would hamper protocol compliance.
- Prior nonpancreatic malignancy treated with chemotherapy. Prior malignancies treated with surgery or radiotherapy alone must be in remission ≥ 3 years. The following prior malignancies are allowable irrespective of when they occurred: in situ carcinoma of the cervix, in situ ductal breast cancer, low-grade local bladder cancer, and nonmelanotic skin cancer.
- Females who are pregnant or breastfeeding.
- Refusal to use adequate contraception for fertile patients (females and males during the study and for 6 months after the last study treatment). Adequate forms of contraception are double-barrier methods (condoms or diaphragm with spermicidal jelly or foam); oral, depot, or injectable contraceptives; intrauterine devices; tubal ligation.
- Any other reason the investigator considers the patient should not participate in the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: gemcitabina
|
1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
|
Experimental: CO-1.01
|
1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Overall Survival in Patients With Low High Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression
Prazo: Monthly follow up after treatment discontinuation until death, up to 1.5 years.
|
Monthly follow up after treatment discontinuation until death, up to 1.5 years.
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Overall Survival in All Patients and Patients With hENT1 Expression
Prazo: Monthly follow up after treatment discontinuation until death, up to 1.5 years
|
Monthly follow up after treatment discontinuation until death, up to 1.5 years
|
ORR, Duration of Response, and Progression Free Survival (PFS) in Patients With Measurable/Evaluable Disease, Using RECIST 1.1, up to 1.5 Years
Prazo: Every 8 weeks
|
Every 8 weeks
|
Cancer Antigen (CA)19-9 Response Rates
Prazo: Every 4 weeks, up to 1.5 years
|
Every 4 weeks, up to 1.5 years
|
Drug Tolerability and Toxicity
Prazo: Every week, up to 1.5 years
|
Every week, up to 1.5 years
|
Change From Baseline in Pain Severity
Prazo: Every 4 weeks, up to 1.5 years
|
Every 4 weeks, up to 1.5 years
|
Change From Baseline in Health Status
Prazo: Every 4 weeks, up to 1.5 years
|
Every 4 weeks, up to 1.5 years
|
Pharmacokinetic (PK) Profile of CO-1.01 Based on Sparse Sampling
Prazo: 30 days after first dose
|
30 days after first dose
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por Tipo Histológico
- Neoplasias
- Carcinoma
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores Enzimáticos
- Antimetabólitos, Antineoplásicos
- Antimetabólitos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Gemcitabina
Outros números de identificação do estudo
- CO-101-001
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em CO-1.01
-
Clovis Oncology, Inc.ConcluídoTumor Sólido AvançadoHolanda
-
Clovis Oncology, Inc.RescindidoCâncer de pulmão | Tumor Sólido | Câncer de Pulmão de Células Não PequenasEstados Unidos, Reino Unido
-
Haukeland University HospitalConcluído
-
IpasRescindidoAborto Induzido | Aborto IncompletoMéxico, África do Sul
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Rick Hansen Foundation; Networks... e outros colaboradoresConcluídoComprometimento cognitivo leveCanadá
-
University of RochesterRecrutamentoCâncerEstados Unidos
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Rick Hansen Foundation; Networks... e outros colaboradoresDesconhecidoComprometimento cognitivo leve | Lesões da Medula Espinhal | Cadeira de rodas motorizadaCanadá
-
George Papanicolaou HospitalAinda não está recrutandoDoença arterial coronária | Doença da Valva Aórtica | Doença da Valva Mitral
-
Yonsei UniversityConcluídoLente de contato coloridaRepublica da Coréia
-
VA Office of Research and DevelopmentConcluído